Key result
Small-molecule TNNI3K inhibitors delivered at reperfusion reduced mitochondrial superoxide generation, p38 activation, and infarct size, preserving cardiac function.
Why the study?
Does TNNI3K inhibition reduce ischemia/reperfusion injury and adverse remodeling in the ischemic heart?
Does TNNI3K inhibition reduce ischemia/reperfusion injury and adverse remodeling in the ischemic heart?
Pharmacologic inhibition of the cardiomyocyte-specific kinase TNNI3K represents a potential cardiac-selective therapeutic strategy to limit reperfusion injury and adverse remodeling in acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
May attenuate reperfusion injury in animals; leaves open translation to human ACS.
Vagnozzi et al. (2013) studied Ischemia/reperfusion injury in acute coronary syndromes. Small-molecule TNNI3K inhibitors was evaluated on Mitochondrial-derived superoxide generation, p38 activation, infarct size, and cardiac function. Small-molecule TNNI3K inhibitors delivered at reperfusion reduced mitochondrial superoxide generation, p38 activation, and infarct size, preserving cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: